GlassScriptPhysician profile
Nashib Hashmi
NPI 1629194543
$14,103.49
in general payments reported to CMS, 2019-2025
38 companies · $2,379 in 2025
The $2,379 reported for 2025 was more than what 90% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,876 · 2020: $1,054 · 2021: $1,512 · 2022: $2,340 · 2023: $2,162 · 2024: $2,781 · 2025: $2,379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,894 · Education: $428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,893.56 |
| Education | $428.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $1,770.89 | 2020-2025 | Acthar |
| Opko Pharmaceuticals, LLC | $1,485.24 | 2019-2025 | Rayaldee |
| Vifor Pharma, INC. | $1,354.93 | 2019-2025 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals LP | $1,294.69 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $1,158.26 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Travere Therapeutics, INC. | $891.08 | 2019-2025 | |
| Novo Nordisk INC | $757.00 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $613.67 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $521.81 | 2021-2025 | |
| Glaxosmithkline, LLC. | $435.18 | 2021-2024 | Benlysta, Jesduvroq |
| Ani Pharmaceuticals, INC. | $432.03 | 2022-2025 | Purified Cortrophin Gel |
| Akebia Therapeutics INC | $429.58 | 2019-2025 | Vafseo |
| Ardelyx, INC. | $378.31 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Novartis Pharmaceuticals Corporation | $339.65 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $322.45 | 2022-2025 | Tarpeyo |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nashib Hashmi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.